A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Conditions: Lymphoma, Non-Hodgkin; Hodgkin Disease Interventions: Drug: Relatlimab; Drug: Nivolumab Sponsor: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2022 Category: Research Source Type: clinical trials
Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients
Condition: Hodgkin Lymphoma Intervention: Sponsor: Federico II University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2022 Category: Research Source Type: clinical trials
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Conditions: Lymphoma, Non-Hodgkin; Hodgkin Disease Interventions: Drug: Relatlimab; Drug: Nivolumab Sponsor: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2022 Category: Research Source Type: clinical trials
Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients
Condition: Hodgkin Lymphoma Intervention: Sponsor: Federico II University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2022 Category: Research Source Type: clinical trials
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Conditions: Lymphoma, Non-Hodgkin; Hodgkin Disease Interventions: Drug: Relatlimab; Drug: Nivolumab Sponsor: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2022 Category: Research Source Type: clinical trials
Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients
Condition: Hodgkin Lymphoma Intervention: Sponsor: Federico II University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2022 Category: Research Source Type: clinical trials
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Conditions: Lymphoma, Non-Hodgkin; Hodgkin Disease Interventions: Drug: Relatlimab; Drug: Nivolumab Sponsor: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2022 Category: Research Source Type: clinical trials
Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients
Condition: Hodgkin Lymphoma Intervention: Sponsor: Federico II University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2022 Category: Research Source Type: clinical trials